PortcoMonitor
What you trackExploreAboutContact
Log inGet started
PortcoMonitor— deep intelligence on the things you care about
AboutContactPrivacyTermsLog in
© 2026 PortcoMonitor
PortcoMonitor
What you trackExploreAboutContact
Log inGet started
Intelligence · Companies

Zoetis

Animal healthwww.zoetis.comZTS $77.31 +2.78 (+3.7%)

Competitor of diagnoVET

Track Zoetis

Latest Zoetis news

  • SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS
    Morningstar · Jul 16, 2026
  • INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines - ZTS
    PR Newswire · Jul 16, 2026
  • Zoetis to acquire vet teleradiology services firm VitalRads
    PE Hub · Jul 16, 2026

    Zoetis has announced the acquisition of veterinary teleradiology services provider VitalRads from Thrive Pet Healthcare. This strategic move expands the company's diagnostic and digital service capabilities within the veterinary market.

  • ZOETIS INC. (ZTS) SHAREHOLDER ALERT Bernstein Liebhard LLP
    GlobeNewswire · Jul 16, 2026
  • Zoetis to acquire VitalRADS to expand veterinary diagnostics platform
    ROI-NJ · Jul 16, 2026
  • Zoetis Earnings Preview: What to Expect
    Barchart · Jul 16, 2026
  • Zoetis Deadline: ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
    The Conway Daily Sun · Jul 16, 2026
  • Zoetis Deadline: ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
    All News Releases · Jul 16, 2026

    A law firm is reminding investors of the upcoming deadline to serve as lead plaintiff in a securities fraud lawsuit against Zoetis. This legal action could impact the company's reputation and financial standing regarding its disclosures during the specified period.

  • Kaplan Fox & Kilsheimer LLP Alerts Zoetis Inc. (NYSE: ZTS) Invest
    The National Law Review · Jul 15, 2026
  • Here's What We Like About Zoetis' (NYSE:ZTS) Upcoming Dividend
    simplywall.st · Jul 15, 2026
  • Zoetis Inc. (ZTS) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact KTMC
    PRNewswire · Jul 15, 2026

    A securities fraud class action lawsuit has been filed against Zoetis regarding alleged misstatements about product adoption. Investors have until July 27, 2026, to seek lead plaintiff status in the litigation.

  • Levi & Korsinsky Reminds Zoetis Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 27, 2026 - ZTS
    PR Newswire · Jul 15, 2026
  • Zoetis launches Lenivia for dog osteoarthritis pain in Canada, EU
    Investing.com · Jul 15, 2026
  • Zoetis Launches Lenivia for Osteoarthritis Pain Management (ZTS)
    GuruFocus · Jul 15, 2026
  • Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
    Financial Post · Jul 15, 2026

    Zoetis has officially launched Lenivia, a long-acting monoclonal antibody therapy for canine osteoarthritis, in Canada and the European Union. This product expansion provides a new revenue stream and strengthens the company's portfolio in animal pain management.

  • Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
    Yahoo Finance · Jul 15, 2026
  • Zoetis Acquired VitalRads. Here’s What That Means For Your Practice
    Vet Candy · Jul 15, 2026
  • J. Safra Sarasin Holding AG Trims Stake in Zoetis Inc. $ZTS
    MarketBeat · Jul 15, 2026
  • Fifth Third Bancorp Purchases 68,180 Shares of Zoetis Inc. $ZTS
    MarketBeat · Jul 15, 2026
  • Zoetis To Acquire VitalRADS To Expand Veterinary Diagnostic Capabilities
    Pulse 2.0 · Jul 15, 2026

Headlines surfaced and scored by PortcoMonitor. Get the full, ranked feed + a daily briefing →

Track Zoetis

Scored news, filings, market data, an AI dossier, and a daily briefing — free.

Start tracking — free

Compare with

  • IDEXX Laboratories
  • Radimal
  • SignalPET
  • Vetology
PortcoMonitor— deep intelligence on the things you care about
AboutContactPrivacyTermsLog in
© 2026 PortcoMonitor

Markets

Updated 7/2/2026
$77.31+2.78 (+3.7%)ZTS · NYSE
Day $75.39 – $77.3852-wk $71.47 – $160.48

Zoetis is the world's leading animal health company, providing a diverse portfolio of medicines, vaccines, and diagnostics for companion animals and livestock. The company's investment narrative is currently centered on navigating competitive and regulatory headwinds, including recent securities class action lawsuits and concerns over product demand, while attempting to leverage its innovation engine to maintain long-term growth.

Market cap
$30.13B
P/E
11.9
Div yield
2.87%
Next earnings
Aug 6, 2026
Analyst rating
Hold
Price target
$118.29 avg (17 analysts)
View detailed analytics →

Business

Updated 7/2/2026
Overview
Zoetis is a global animal health company that discovers, develops, and manufactures vaccines, medicines, diagnostics, and digital solutions for companion animals and livestock. The company serves veterinarians, pet owners, and livestock producers by providing products to predict, prevent, detect, and treat animal diseases. It generates revenue through the commercialization of its extensive portfolio of animal health products and services worldwide.
Website
www.zoetis.com
Industry
Animal health
Founded
1952
LinkedIn
Company page

Key People

Updated 7/2/2026
  • Kristin PeckCEO
    Edu: Columbia Business School
    Prior: EVP & Group President, U.S. Operations @ Zoetis · EVP, Worldwide Business Development and Innovation @ Pfizer
  • Wetteny JosephEVP & Chief Financial Officer
    Edu: Florida Atlantic University
    Prior: SVP & CFO @ Catalent · CFO, Plumbing & HVAC Business Unit @ HD Supply
  • Jamie BrannanEVP & Chief Commercial Officer
  • Nick AshtonEVP & President, Global Manufacturing and Supply
  • Paul M. BisaroBoard Member
    Edu: University of Michigan
    Prior: Executive Chairman @ Impax Laboratories · CEO @ Actavis
  • Frank A. D'AmelioBoard Member
    Edu: St. John's University
    Prior: CFO @ Pfizer · CFO @ Alcatel-Lucent

Funding

Updated 7/2/2026

Total raised: $2.2B

  • $2.2BIPO· Feb 2013
    Reported — from announcements